Insys Therapeutics (INSY) Announces Buprenorphine Sublingual Spray Phase 3 Met Primary Endpoint
- Wall St stocks end higher with major corporate earnings in view
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
- Tesla expands price cuts to China, Germany after reducing FSD cost; shares down
- Gold prices slide as M.East fears ease, rate jitters persist
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
INSYS Therapeutics (INSY) Bullish View Reiterated at Piper Jaffray Following Favorable Buprenorphine Data
August 24, 2016 3:59 PM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and $28 price target on INSYS Therapeutics (NASDAQ: INSY) reported positive top-line results from a Phase III trial evaluating its sublingual spray form of buprenorphine for post-operative pain following bunionectomy surgery.
Amsellem... More